Numinus Wellness Inc. Announces First Quarter Fiscal 2025 Results

Rhea-AI Summary

Numinus Wellness (OTCQB: NUMIF), a mental health care company specializing in psychedelic-assisted therapies, reported its Q1 2025 financial results. The company achieved significant revenue growth of 68.3%, reaching $2.01 million compared to $1.20 million in Q1 2024.

The company demonstrated improved operational efficiency with a gross profit margin increase to 49.3% from 38.6% year-over-year. Operating expenses decreased substantially by 51.1% to $2.07 million. The net loss narrowed to $1.29 million from $4.35 million in the prior year. As of November 30, 2024, Numinus maintained a cash position of $2.0 million.

Positive

• None.

Negative

• Cash position remains relatively low at $2.0 million
• Company continues to operate at a loss despite improvements

All financial results are reported in Canadian dollars unless otherwise stated.

Vancouver, British Columbia--(Newsfile Corp. - August 8, 2025) - Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended November 30, 2024 ("Q1 2025").

Q1 2025 Performance Metrics

		For the quarter ended:
		Nov 30, 2024 (Q1 2025)			Nov 30, 2023 (Q1 2024)			% change
Total Revenue	$	2,013,779		$	1,196,629			68.3%
Cost of revenue		992,622			734,686			35.1%
Gross Profit (Loss)	$	1,021,157		$	461,943			121.1%
Gross profit margin (loss)		49.3%			38.6%			107 bps
Operating expenses and other items		2,065,596			4,226,850			-51.1%
Loss and comprehensive loss		($1,286,464	)		($4,351,472	)		n/a

 

Balance Sheet and Liquidity
Numinus ended the quarter with cash and cash equivalents of $2.0 million.

Numinus' unaudited condensed consolidated interim financial statements for the three months ended November 30, 2024, and related management's discussion and analysis are available on Numinus' Investor Relations website at www.investors.numinusnetwork.com and under the Company's profile on SEDAR+ at www.sedarplus.ca. These documents were prepared in accordance with IFRS.

About Numinus
Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model — including psychedelic research and clinic care — is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at www.numinusnetwork.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.

SOURCE: Numinus Wellness Inc.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including, without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are "forward-looking statements". Forward-looking statements can be identified by the use of words such as "expects", "does not expect", "is expected", "believes", "intends", "anticipates", "does not anticipate", "believes" or variations of these words, expressions or statements, that certain actions, events or results "may", "could", "would", "might" or "will be" taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, ability of Numinus to maintain or increase earnings; ability of Numinus to achieve or maintain profitability; results of changes to operations from a financial or business perspective; the effect of cost containment measures on Numinus business and financial position; changes to cash burn rate, expenses, corporate programs or priorities, or unanticipated costs affecting cash runway or the pathway to positive cashflow or profitability, the effect of any transaction or other activity undertaken by the company in connection with the strategic review; interest in, uptake of and the ability to commercialize the Numinus Training; availability of subjects and trainers for experiential opportunities in practitioners training, if approved; dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate the Company's facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal, state and provincial legalization, if any, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company's need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers; and other risk factors set forth in our annual information form dated July 25, 2025 and available on SEDAR+ at www.sedarplus.ca. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company's efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws.

For more information:
Investor Contact
Craig MacPhail
invest@numinusnetwork.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/261892

FAQ

What was Numinus Wellness (NUMIF) revenue in Q1 2025?

Numinus reported revenue of $2.01 million in Q1 2025, representing a 68.3% increase from $1.20 million in Q1 2024.

How much did Numinus (NUMIF) reduce its losses in Q1 2025?

Numinus reduced its net loss to $1.29 million in Q1 2025, down significantly from $4.35 million in Q1 2024.

What is Numinus Wellness's (NUMIF) cash position as of Q1 2025?

Numinus ended Q1 2025 with $2.0 million in cash and cash equivalents.

How did Numinus (NUMIF) improve its gross profit margin in Q1 2025?

Numinus improved its gross profit margin to 49.3% in Q1 2025, up from 38.6% in Q1 2024, representing a 107 basis point improvement.

What was the reduction in operating expenses for Numinus (NUMIF) in Q1 2025?

Numinus reduced its operating expenses by 51.1% to $2.07 million compared to $4.23 million in Q1 2024.